Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

HER2, HER3, and TROP2: An Update on Novel Treatments for Key Targets
  • CME

Credits Available
Physicians: maximum of 2.0 AMA PRA Category 1 Credits
Released: May 11, 2022 Expiration: May 10, 2023
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Aditya Bardia, MD, MPH
Yelena Y. Janjigian, MD
Sandip P. Patel, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Review the most recent evidence-based guidelines and expert recommendations for assessing HER2, HER3, and TROP2 in the metastatic setting for breast, gastrointestinal, and lung cancers
  • Appraise the latest available clinical data for established and emerging HER2-, HER3-, and TROP2-targeted therapies in breast, gastrointestinal, and lung cancers
  • Implement best practices for HER2, HER3, and TROP2 diagnostic testing and interpretation to guide integration of the latest targeted therapies into individualized treatment plans
  • Identify patients eligible to enroll on important ongoing clinical trials based on evaluating novel HER2-, HER3-, and TROP2-targeted therapies in breast, gastrointestinal, and lung cancers

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Aditya Bardia, MD, MPH

Director, Breast Cancer Research
Associate Professor
Harvard Medical School
Attending Physician
Massachusetts General Hospital
Boston, Massachusetts

Aditya Bardia, MD, MPH, has disclosed that he has received consulting fees from Daiichi Pharma/AstraZeneca, Foundation Medicine, Genentech, Immunomedics/Gilead, Lilly, Merck, Novartis, Pfizer, Phillips, Radius Health, and Sanofi and research funds paid to his institution from Daiichi Pharma/AstraZeneca, Genentech, Immunomedics/Gilead, Lilly, Merck, Novartis, Pfizer, Radius Health, and Sanofi.
Yelena Y. Janjigian, MD

Associate Attending Physician
Chief, 
Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Yelena Y. Janjigian, MD, has disclosed that she has received consulting fees from AstraZeneca, Basilea Pharmaceutica, Bayer, Bristol-Myers Squibb, Daiichi Sankyo, Genentech/Roche, Imugene, Lilly, Merck, Merck Serono, RGENIX, Seagen, and Zymeworks; has received research funds paid to her institution from Bayer, Bristol-Myers Squibb, Lilly, Merck, and RGENIX; and has stock options from RGENIX.
Sandip P. Patel, MD

Associate Professor
Division of Hematology and Medical Oncology
UC San Diego Moores Cancer Center
La Jolla, California

Sandip P. Patel, MD, has disclosed that he has received consulting fees from Amgen, AstraZeneca, Bristol-Myers Squibb, Certis, Genentech, Illumina, Lilly, Merck, Pfizer, Rakuten, and Tempus and research funds paid to his institution from Amgen, AstraZeneca/MedImmune, Bristol-Myers Squibb, Fate Therapeutics, Iovance, Lilly, Merck, Pfizer, Roche/Genentech, and SQZ Biotechnologies.

Staff

Marie N. Becker, PhD

Scientific Director

Marie N Becker, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has disclosed he had individual publicly traded stocks/options in AstraZeneca.
Brian Purves
Brian Purves has disclosed he was an employee of AstraZeneca (employment ended 8/2021).
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for oncologists and other healthcare professionals who care for patients with breast, gastrointestinal, and lung cancers.

Goal

The goal of this activity is to improve the knowledge, competence, and performance of learners to facilitate understanding and integration into clinical practice of the most relevant data on biomarker-guided, targeted treatment of various HER2-, HER3-, and TROP2-altered metastatic cancers, including breast, gastrointestinal, and lung.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 2.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 11, 2022, through May 10, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

HER2, HER3, and TROP2: An Update on Novel Treatments for Key Targets
  • CME

Loading...
In this on-demand webcast from a recent AACR satellite symposium, expert faculty highlight the latest evidence on the optimal use of HER2, HER3, and TROP2 antibody–drug conjugates in breast, gastrointestinal, and lung cancers.
Aditya Bardia, MD, MPH
Yelena Y. Janjigian, MD
Sandip P. Patel, MD
Physicians: maximum of 2.0 AMA PRA Category 1 Credits
Released: May 11, 2022 Expiration: May 10, 2023

Related Content

Downloadable clinical resource with practical guidance on how to talk with your transgender patients about gender identity, including related terminology, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD
Program Director
Released: June 30, 2022

Commentary from Nelson F. Sanchez, MD, on caring for transgender individuals, from the healthcare disparities they face to how healthcare professionals can improve their care, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD
Program Director
Released: June 28, 2022

Update of ATEZO-BRAIN trial evaluating atezolizumab plus chemotherapy in patients with advanced nonsquamous NSCLC with untreated brain metastases, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 16, 2022

Results from LUMINA trial showing very low local recurrence rate with omission of radiotherapy after breast-conserving surgery in patients with low-risk luminal A breast cancer, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 15, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings